​

Dyne Therapeutics (DYN) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

DYN Stock Forecast

Dyne Therapeutics (DYN) stock forecast, based on 14 Wall Street analysts, predicts a 12-month average price target of $35.50, with a high of $47.00 and a low of $24.00. This represents a 48.60% increase from the last price of $23.89.

$10 $18 $26 $34 $42 $50 High: $47 Avg: $35.5 Low: $24 Last Closed Price: $23.89

DYN Stock Rating

Dyne Therapeutics stock's rating consensus is Buy, based on 14 Wall Street analysts. The breakdown includes 1 Strong Buy (7.14%), 11 Buy (78.57%), 2 Hold (14.29%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 14 0 2 11 1 Strong Sell Sell Hold Buy Strong Buy

DYN Price Target Upside V Benchmarks

TypeNameUpside
StockDyne Therapeutics48.60%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-217
Avg Price Target-$28.50$34.71
Last Closing Price$23.89$23.89$23.89
Upside/Downside-19.30%45.29%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 263122--17
Jun, 263112--16
May, 263112--16
Apr, 263112--16
Mar, 263112--16
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 15, 2026Evercore ISI$33.00$17.7985.50%38.13%
May 13, 2026Bernstein$24.00$18.3730.65%0.46%
Mar 02, 2026Keay NakaeChardan Capital$38.00$16.15135.29%59.06%
Mar 02, 2026Michael E UlzMorgan Stanley$47.00$15.68199.74%96.74%
Dec 15, 2025Gavin Clark-GartnerEvercore ISI$36.00$19.5184.52%50.69%
Dec 11, 2025Stifel Nicolaus$39.00$19.6998.07%63.25%
Dec 10, 2025Oppenheimer$40.00$18.44116.92%67.43%
Dec 09, 2025William PickeringTudor Pickering$23.00$19.0920.48%-3.73%
Dec 09, 2025Bernstein$23.00$22.203.60%-3.73%
Dec 08, 2025Michael E UlzMorgan Stanley$50.00$22.20125.23%109.29%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jul 23, 2026Cantor FitzgeraldOverweightinitialise
Jun 26, 2026Cowen & Co.BuyBuyinitialise
May 13, 2026BernsteinMarket PerformMarket Performhold
Mar 09, 2026JefferiesBuyBuyhold
Mar 02, 2026Morgan StanleyOverweightOverweighthold
Dec 15, 2025Evercore ISIOutperformOutperformhold
Dec 10, 2025OppenheimerPerformOutperformupgrade
Dec 08, 2025Morgan StanleyOverweightOverweighthold
Dec 08, 2025Cowen & Co.BuyBuyhold
Dec 08, 2025H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.95$-3.37$-3.47---
Avg Forecast$-3.78$-3.47$-3.76$-3.83$-3.12$-1.16
High Forecast$-3.61$-3.16$-2.83$-3.10$-1.76$-1.16
Low Forecast$-3.95$-3.84$-4.75$-4.79$-3.92$-1.16
Surprise %4.50%-2.88%-7.71%---

Revenue Forecast

$0 $110M $220M $330M $440M $550M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast--$833.33K$9.56M$192.28M$500.80M
High Forecast--$833.33K$9.56M$192.28M$500.80M
Low Forecast--$833.33K$9.56M$192.28M$500.80M
Surprise %------

Net Income Forecast

$-450M $-370M $-290M $-210M $-130M $-50M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-235.94M$-317.42M$-446.21M---
Avg Forecast$-225.57M$-208.96M$-226.32M$-235.37M$-169.58M$-69.23M
High Forecast$-215.66M$-188.82M$-169.04M$-184.84M$-105.33M$-69.23M
Low Forecast$-235.48M$-229.11M$-283.60M$-285.89M$-233.82M$-69.23M
Surprise %4.60%51.90%97.16%---

DYN Forecast FAQ

Is Dyne Therapeutics stock a buy?

Dyne Therapeutics stock has a consensus rating of Buy, based on 14 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 11 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Dyne Therapeutics is a favorable investment for most analysts.

What is Dyne Therapeutics's price target?

Dyne Therapeutics's price target, set by 14 Wall Street analysts, averages $35.5 over the next 12 months. The price target range spans from $24 at the low end to $47 at the high end, suggesting a potential 48.60% change from the previous closing price of $23.89.

How does Dyne Therapeutics stock forecast compare to its benchmarks?

Dyne Therapeutics's stock forecast shows a 48.60% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Dyne Therapeutics over the past three months?

  • July 2026: 17.65% Strong Buy, 70.59% Buy, 11.76% Hold, 0% Sell, 0% Strong Sell.
  • June 2026: 18.75% Strong Buy, 68.75% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 18.75% Strong Buy, 68.75% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.

What is Dyne Therapeutics’s EPS forecast?

Dyne Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-3.83, marking a 10.37% increase from the reported $-3.47 in 2025. Estimates for the following years are $-3.12 in 2027, and $-1.16 in 2028.

What is Dyne Therapeutics’s revenue forecast?

Dyne Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $9.56M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $192.28M, and $500.8M for 2028.

What is Dyne Therapeutics’s net income forecast?

Dyne Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-235M, representing a -47.25% decrease from the reported $-446M in 2025. Projections indicate $-170M in 2027, and $-69.233M in 2028.